<DOC>
	<DOCNO>NCT00715637</DOCNO>
	<brief_summary>Amonafide DNA intercalate agent inhibitor topoisomerase II extensively study patient malignant solid tumor . Amonafide also study patient AML . The purpose study assess relative efficacy safety amonafide combination cytarabine compare daunorubicin cytarabine subject document secondary AML .</brief_summary>
	<brief_title>Phase III Randomized Study Amonafide ( AS1413 ) Cytarabine Versus Daunorubicin Cytarabine Patients With Secondary Acute Myeloid Leukemia ( AML ) - ACCEDE Study</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Amonafide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Diagnosis AML accord WHO diagnostic criterion ( least 20 % blast peripheral blood bone marrow ) , FAB classification M3 ( Acute Promyelocytic Leukemia ) , document bone marrow aspiration biopsy perform within 14 day prior administration 1st dose remission induction chemotherapy ; Either : Known documented exposure specific leukemogenic therapy specify nature nonmyeloid condition ; OR Documented diagnosis MDS accord WHO criteria least 3 month prior study entry , prior bone marrow aspirate , biopsy peripheral blood smear document MDS available submit subsequent central pathology review . Age 18 year old ; Eastern Cooperative Oncology Group ( ECOG ) performance score = &lt; 2 ; Fertile sexually active patient ( men woman ) must use effective method contraception must continue throughout study . Women childbearing potential must negative serum pregnancy test . Left Ventricular Ejection Fraction ( LVEF ) &gt; = 50 % , determine multiplegated acquisition scan ( MUGA ) echocardiogram ( ECHO ) within 14 day prior administration 1st dose remission induction chemotherapy ; Adequate renal function evidence follow laboratory test , obtain within 10 day prior administration 1st dose remission induction chemotherapy : Serum creatinine = &lt; 1.5 x ULN ; Adequate hepatic function evidence follow laboratory test , obtain within 10 day prior administration 1st dose remission induction chemotherapy ( unless attribute hepatic involvement AML ) : Total serum bilirubin = &lt; 1.5 x ULN ; Serum AST ALT = &lt; 1.5 x ULN ; Ability patient participate fully aspects clinical trial ; Written Informed Consent HIPAA authorization ( USA sit ) must obtain document . Histologic diagnosis FAB M3 Acute Promyelocytic Leukemia ; Clinically active CNS leukemia ; Prior induction therapy AML ; Known HIV positive ; Known active hepatitis B C , active liver disease ; Patients parenchymal abnormality screen chest xray must evidence pulmonary infection chest tomography ( CT ) prior start remission induction therapy . Any major surgery radiation therapy within 4 week prior study entry ; Prior cytotoxic chemotherapy MDS within 4 week prior study entry ( patient rapidly rise blast count may enrol within 4 week prior cytotoxic chemotherapy waiver Medical Monitor ) ; Persistent chronic nonhematologic toxicity ( alopecia ) great grade 1 prior therapy MDS ; Serious concomitant illness ( example , pulmonary infiltrate , unstable angina myocardial infarction stroke within 3 month prior study entry , congestive heart failure AHA class 2 great , uncontrolled hypertension , uncontrolled diabetes , actively bleed gastric ulcer , etc . ) , investigator 's opinion would make patient good candidate trial ; Pregnant breast feeding ; History clinically significant allergic reaction attribute compound similar chemical biological composition amonafide , cytarabine daunorubicin ; Prior enrollment trial ; Any know condition ( e.g. , familial , sociological , geographical ) behavior ( include substance dependence abuse , psychological psychiatric illness ) , investigator 's opinion would make patient poor candidate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>AML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>MDS</keyword>
	<keyword>Amonafide</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Daunorubicin</keyword>
	<keyword>Lymphatic disorder</keyword>
</DOC>